151 related articles for article (PubMed ID: 30951933)
1. RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
Mu XY; Wang RJ; Yao ZX; Zheng Z; Jiang JT; Tan MY; Sun F; Fan J; Wang X; Zheng JH; Wu K; Liu ZH
Mol Immunol; 2019 May; 109():140-148. PubMed ID: 30951933
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy.
Wu K; Tan MY; Jiang JT; Mu XY; Wang JR; Zhou WJ; Wang X; Li MQ; He YY; Liu ZH
Clin Immunol; 2018 Aug; 193():60-69. PubMed ID: 29410331
[TBL] [Abstract][Full Text] [Related]
4. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
Sasso MS; Lollo G; Pitorre M; Solito S; Pinton L; Valpione S; Bastiat G; Mandruzzato S; Bronte V; Marigo I; Benoit JP
Biomaterials; 2016 Jul; 96():47-62. PubMed ID: 27135716
[TBL] [Abstract][Full Text] [Related]
5. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
6. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer.
Yang G; Shen W; Zhang Y; Liu M; Zhang L; Liu Q; Lu HH; Bo J
Oncotarget; 2017 Jun; 8(24):38378-38388. PubMed ID: 28418913
[TBL] [Abstract][Full Text] [Related]
8. CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid-derived suppressor cells.
Gu H; Deng W; Zheng Z; Wu K; Sun F
Immun Inflamm Dis; 2021 Dec; 9(4):1686-1695. PubMed ID: 34525267
[TBL] [Abstract][Full Text] [Related]
9. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
10. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
[TBL] [Abstract][Full Text] [Related]
11. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
12. Analgesic effects evoked by a CCR2 antagonist or an anti-CCL2 antibody in inflamed mice.
Llorián-Salvador M; Pevida M; González-Rodríguez S; Lastra A; Fernández-García MT; Hidalgo A; Baamonde A; Menéndez L
Fundam Clin Pharmacol; 2016 Jun; 30(3):235-47. PubMed ID: 26820818
[TBL] [Abstract][Full Text] [Related]
13. Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment.
Oo MW; Kawai H; Takabatake K; Tomida S; Eguchi T; Ono K; Shan Q; Ohara T; Yoshida S; Omori H; Sukegawa S; Nakano K; Okamoto K; Sasaki A; Nagatsuka H
JCI Insight; 2022 Jan; 7(1):. PubMed ID: 34874922
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment.
Ouyang L; Chang W; Fang B; Qin J; Qu X; Cheng F
Sci Rep; 2016 Dec; 6():39541. PubMed ID: 27996037
[TBL] [Abstract][Full Text] [Related]
15. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Kim NR; Kim YJ
Cancer Med; 2019 Jan; 8(1):276-288. PubMed ID: 30592157
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
18. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model.
Danishmalik SN; Sin JI
DNA Cell Biol; 2017 Sep; 36(9):801-811. PubMed ID: 28777668
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.
Liang T; Tao T; Wu K; Liu L; Xu W; Zhou D; Fang H; Ding Q; Huang G; Wu S
Adv Sci (Weinh); 2023 Nov; 10(31):e2303230. PubMed ID: 37743226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
